🧬 VITILIGO IN REVIEW: Catch up on the latest news on vitiligo advancements in 2024, including real-world patient experiences, consensus-based recommendations for pediatrics, and more. https://lnkd.in/gjThfPjK
About us
Dermatology Times is a leading news resource serving more than 16,000 dermatologists and other skin care professionals and focusing on the latest developments in dermatological practice, regulatory news, practice management, and new products. We strive to help practitioners understand and put into perspective developments that affect their profession and their business.
- Website
-
http://www.dermatologytimes.com
External link for Dermatology Times
- Industry
- Book and Periodical Publishing
- Company size
- 501-1,000 employees
- Headquarters
- Cranbury
- Type
- Public Company
Locations
-
Primary
Cranbury, US
Employees at Dermatology Times
Updates
-
📈 NEW DATA: Alumis Inc. recently announced promising results from the open-label extension of its phase 2 STRIDE clinical trial for ESK-001 in #psoriasis at #EADV24. 93% of patients receiving the highest dose of 40 mg twice daily achieved PASI 75. 🖇 Read more: https://lnkd.in/gjkVts8D
Promising Long-term Results for ESK-001 in Psoriasis
dermatologytimes.com
-
📰 The September issue of Dermatology Times includes a collection of thought-provoking articles and topics ranging from addressing myths related to botulinum toxins to case reviews of pseudo acne fulminans. Be sure to read the highlights from the issue below. ⬇️ https://lnkd.in/g7craKXi
Dermatology Times September 2024 Print Recap
dermatologytimes.com
-
💡 EXPERT INSIGHTS: Gil Yosipovitch, MD, discusses the importance of differentiating between #atopicdermatitis and #prurigonodularis, including differences in prominent cytokine pathways, patient populations affected, and more. "In atopic dermatitis, the barrier disruption is a major key driver and the disease is more epidermal in origin, while in prurigo nodularis, it’s more of a dermal-epidermal process and the barrier damage is secondary," Yosipovitch said. 🖇 Read more: https://lnkd.in/g2zdS_nD
Recognizing Key Differences Between Atopic Dermatitis and Prurigo Nodularis
dermatologytimes.com
-
📈 NEW DATA: UCB recently announced groundbreaking 2-year data from its phase 3 studies, BE HEARD I and BE HEARD II, regarding the efficacy and safety of #bimekizumab in #hidradenitissuppurativa at #EADV24. Researchers reported sustained improvements over 2 years and quality of life enhancements for patients. 🖇 Read more: https://lnkd.in/gdPwQaUb
2-Year Study Affirms Bimekizumab's Efficacy in Hidradenitis Suppurativa
dermatologytimes.com
-
🗞 IN THE NEWS: Review our rundown of the latest headlines in dermatology from the past week, including regulatory updates for bimekizumab and roflumilast, data on semaglutide and HS, and more. https://lnkd.in/gWtdtku2
-
📹 DERMVIEW: Learn about the challenges of managing pediatric plaque psoriasis with Karan Lal, DO, and Helen T. Shin, MD. Watch here: https://ow.ly/jlBS50TBeH6
-
🌟 EXPERT INSIGHTS: Melinda Gooderham, MSc, MD, FRCPC, details the results of the ADjoin long-term extension trial evaluating the 3-year safety and efficacy data of lebrikizumab in #atopicdermatitis. #EADV24 🎥 Watch the full interview now: https://lnkd.in/gYEAngTq
Melinda Gooderham, MSc, MD, FRCPC: Insights Into Lebrikizumab’s Sustained 3-Year Efficacy
dermatologytimes.com
-
🌟 EXPERT INSIGHTS: Arash Mostaghimi, MD, MPA, MPH, recently provided insight into the THRIVE-AA1 and THRIVE-AA2 trials and the significance of #deuruxolitnib’s efficacy in patients with severe #alopeciaareata. #EADV24 🖇 Read more: https://lnkd.in/emNqKdbn
Deuruxolitinib Shows Efficacy in Hair Regrowth, Patient Satisfaction, and Psychosocial Wellbeing in Severe Alopecia Areata
dermatologytimes.com
-
📈 NEW DATA: Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) shared new data from INTEGUMENT-1 and INTEGUMENT-2 for #atopicdermatitis, reporting that #roflumilast cream 0.15% (Zoryve; Arcutis) demonstrates consistent efficacy and safety across different racial, ethnic, and Fitzpatrick skin types. 🖇 Read more: https://lnkd.in/eUywUfxE
Positive Results Reported in Roflumilast 0.15% for AD Across Diverse Populations
dermatologytimes.com